Peerbridge Cor(TM) System

by Peerbridge Health  · Based in United States →Elevating Ambulatory ECG
Cardiology

Contact for pricing
Regulatory Status Disclosed

Overview

The Peerbridge Cor™ System is an FDA-cleared, AI-enabled ambulatory ECG system designed to revolutionize cardiac care by bringing hospital-grade diagnostics and monitoring into the home and clinical settings. It pairs a comfortable, wearable patch with a clinic-friendly, cloud-based platform that integrates seamlessly into existing workflows. The system captures high-fidelity physiological signals, including 31 cardiac rhythms, using a patented multi-lead, 2-channel wireless AECG patch with an Einthoven’s Triangle design. Its proprietary AI algorithm can compute a derived 12-lead ECG, providing a volumetric view of the heart from a simple patch.

The Peerbridge Cor™ System is intended for continuous external electrocardiogram (ECG) information capture for 24 hours and up to 7 days, as well as patient-activated event monitoring. It is indicated for adult patients (18 or older) who may be asymptomatic or experience transient symptoms such as palpitations, shortness of breath, dizziness, or fatigue. The platform transforms complex data into clear, decision-ready insights, enabling faster answers and earlier intervention. Beyond rhythm monitoring, Peerbridge Health is expanding capabilities to include AI-driven diagnostics for heart failure, ejection fraction severity, and obstructive sleep apnea directly from ECG data, with ongoing clinical trials for these advanced indications. The system aims to provide cost-effective, accessible, and accurate cardiac diagnostics, addressing the growing need for better cardiac care and the shortage of cardiologists.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • FDA-cleared ambulatory ECG system
  • Wearable, multi-lead, 2-channel wireless AECG patch
  • Einthoven's Triangle design for high-fidelity signal quality
  • Captures 31 cardiac rhythms
  • Proprietary AI algorithm for derived 12-lead ECG
  • Cloud-based platform for decision-ready reports
  • Seamless integration into existing clinical workflows
  • Patient-activated event button and mobile application for symptom reporting
  • Continuous monitoring for up to 7 days
  • AI-enabled diagnostics for heart failure, ejection fraction, and sleep apnea (pipeline/trials)

Use Cases

  • Early detection and triage of cardiac conditions
  • Ambulatory ECG monitoring (Holter, extended Holter, event monitoring)
  • Diagnosis and monitoring of cardiac arrhythmias (e.g., atrial fibrillation)
  • Remote monitoring and early detection of heart failure
  • Diagnosis of obstructive sleep apnea (OSA) from ECG
  • Primary care screening and on-demand cardiac diagnostics

What Physicians Need to Know

ECG/EKG Analysis Capability
The Peerbridge Coru2122 System is an FDA-cleared ambulatory ECG system that captures high-fidelity signals, including 31 cardiac rhythms, with clear P-wave definition and precise QRS morphology. It can derive a full 12-lead ECG from a simple patch, traditionally requiring an in-hospital system. The device provides continuous, multi-channel ECG recording for up to 7 days (Cor 1.0) or 14 days (Cor MDx/Cor 2.0). Quantitative analysis on reports includes metrics like QT/QTc and HRV. The COR-INSIGHT trial is evaluating its ability to detect over 30 cardiac and cardiopulmonary indications directly from ECG.
Arrhythmia Detection Accuracy
The system captures 31 cardiac rhythms with high-fidelity signal quality. In a clinical trial, the Peerbridge Coru2122 demonstrated superiority to traditional Holter monitors in detecting atrial fibrillation (AF) and other arrhythmias. The COR-INSIGHT trial is validating its screening and diagnostic capabilities for various cardiovascular indications.
Heart Failure Risk Prediction
The Peerbridge Coru2122 has been validated through prospective trials to detect Heart Failure and estimate Ejection Fraction directly from the device. The Cor MDx is designed to expand access to early detection and intervention for undiagnosed heart failure. The COR-INSIGHT trial is further evaluating its ability to provide insights into heart failure and ejection fraction severity.
Cardiac Monitoring Integration
The Peerbridge Coru2122 system is designed for seamless integration into existing clinical workflows. The Cor MDx offers real-time multi-lead streaming and connectivity over BLE and LTE, with AT&T providing the IoT backbone for real-time data transmission and remote study reconfiguration. The system includes a wearable ECG sensor with Bluetooth, a dedicated handheld transmitter, and a cloud-based backend data management module.
AHA/ACC Guideline Alignment
The COR-INSIGHT trial utilizes a GenAI model to produce explainable traces for clinicians, demonstrating how risk stratification decisions align with standard care guidelines.
Real-Time Alert Capability
The Cor MDx enables real-time data transmission and continuous cardiac monitoring. The COR 2.0 (Cor MDx) offers a 'Real-Time Streaming Mode' for immediate waveform rendering and analysis. The system also includes patient-activated event logging functionality and a dedicated handheld transmitter for event transmission.
Physician Tip

The Peerbridge Coru2122 System offers a comprehensive ambulatory ECG solution with AI-enabled diagnostics, providing high-fidelity signals for precise rhythm and morphology analysis. Its ability to derive a 12-lead ECG from a wearable patch and estimate ejection fraction directly from ECG can streamline diagnostics and reduce the need for more invasive or complex imaging. The system's focus on early detection of arrhythmias and heart failure, coupled with seamless integration into existing workflows and real-time data transmission, makes it a valuable tool for remote patient monitoring and proactive cardiac care. Consider its utility for patients requiring extended monitoring, those in rural areas with limited access to specialists, and for early screening of conditions like heart failure and sleep apnea.

The Peerbridge Coru2122 System is designed for seamless integration into clinical workflows, leveraging a cloud-based backend data management module for analysis and reporting. The Cor MDx model enhances this with real-time multi-lead streaming and cellular connectivity (LTE via AT&T), enabling remote study reconfiguration and continuous data transmission. This robust connectivity facilitates integration with existing electronic health record (EHR) systems and telemedicine platforms, supporting remote patient management and virtual cardiology appointments.

Details

Category Cardiology AI, Wearables & Remote Monitoring (RPM)
Pricing Contact for pricing
  • Contact for pricing; emphasizes low-cost and physician-favorable billing model, aiming to reduce healthcare costs significantly
DeploymentCloud-based Backend Data Management Module
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

The Peerbridge Cor™ System (K171936) received 510(k) clearance from the U.S. Food and Drug Administration (FDA) on September 27, 2017, as an ambulatory ECG system. It is intended to capture and transmit symptomatic events and continuous external ECG information for 24 hours and up to 7 days.

Integrations
EHR Not specified
Specialties Cardiology

What the Web Says

The Peerbridge Coru2122 System is an FDA-cleared, AI-powered wearable ambulatory ECG monitor designed for remote cardiac and cardiopulmonary monitoring. It aims to provide early detection and diagnosis of various heart conditions, including heart failure and arrhythmias, as well as obstructive sleep apnea, with high accuracy. The system is designed to integrate seamlessly into clinical workflows, offering a comfortable patient experience and physician-favorable billing.

Overall: Positive

Strengths

  • High accuracy in detecting heart failure (95.7%) and obstructive sleep apnea (91.2%).
  • Captures 31 cardiac rhythms with high-fidelity signal quality.
  • Comfortable and discreet wearable design.
  • Integrates seamlessly into existing clinical workflows, reducing administrative burden.
  • Enables earlier intervention and informed decision-making for physicians.
  • Cost-effective and patient-friendly, reducing hospital visits and diagnostic time.

Limitations

  • No readily available negative reviews or opinions from physicians, healthcare IT, tech reviewers, Reddit, G2, or Capterra were found in the search results.
  • The COR 2.0 units are experimental and not yet FDA-cleared.
  • Some general wearable ECG monitors can have high false-positive rates in certain populations and disparities in access.
  • General patient experiences with heart monitors (not specific to Peerbridge Cor) mention discomfort from adhesive or anxiety about the device.

Based on reviews from: Peerbridge Health, Diagnostic and Interventional Cardiology, ClinicalTrials.gov, Cardiac Rhythm News, Healthcare Dive, Sleep Review, Myocarditis Foundation, Acorn Product Development, Mount Sinai - New York, Reddit, FDA, RhythmScience

Last updated: 2026-07-18

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Peerbridge Cor(TM) System

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money
No press coverage or publications on file yet. Know of some? Suggest an edit →

Videos

Product demos, reviews, and walkthroughs for Peerbridge Cor(TM) System.

No videos found. Search YouTube directly

View all on YouTube

Frequently Asked Questions

The Peerbridge Coru2122 System is AI-enabled, utilizing proprietary algorithms to analyze high-fidelity ECG signals and detect up to 31 cardiac rhythms, as well as calculate metrics like AHI for sleep apnea and ejection fraction severity. Its approach is grounded in physiological principles, not 'black-box deep learning,' which allows for clear explanations to clinicians regarding its conclusions.
The Peerbridge Coru2122 System is FDA-cleared (510(k) clearance) as an extended Holter monitor, with its reports generated by FDA-cleared algorithms. While HIPAA is not explicitly mentioned in the search results, FDA-cleared medical devices handling patient data are generally expected to adhere to privacy regulations. The system is designed to integrate into existing clinical workflows, implying adherence to healthcare data standards.
The system is designed to integrate seamlessly into existing clinical workflows, providing consistent, decision-ready reports without adding administrative burden. Physicians can use it for continuous ambulatory ECG monitoring (24 hours up to 7 days, and 14 days with Cor MDx), patient-activated event logging, and obtaining insights for early detection and intervention in various settings, including outpatient, in-hospital, and home environments.
Alternatives to the Peerbridge Coru2122 System include traditional Holter monitors, other ECG patch monitors, mobile cardiac telemetry (MCOT), and implantable loop recorders. Peerbridge Cor is presented as a 'true Holter Monitoring replacement' that offers multi-lead, high-fidelity ECG data from a comfortable wearable, aiming to provide earlier detection and more comprehensive diagnostics than some traditional methods, and can derive a 12-lead ECG from a simple patch.
While specific pricing details are not provided, the Peerbridge Coru2122 System is described as 'cost-effective,' 'ultra-low cost,' and 'inexpensive,' with a 'physician-favorable billing model.' It aims to keep billing with the physician and clinic, supporting predictable margins and straightforward reconciliation, and is approved for multiple insurance codes to reduce economic burden.
One potential challenge for patch monitors in general, which could apply, is that each vendor may require its own portal, limiting multi-OEM integration. While the AI is transparent, it's grounded in physiological principles rather than 'black-box deep learning,' which might imply different capabilities compared to other AI approaches. The second-generation device, Cor MDx, is currently under FDA review, indicating that some advanced features are still pending full clearance.
The Peerbridge Coru2122 System, particularly with its advanced AI platforms like CardioMIND and CardioQSync, is designed to diagnose and monitor over 30 cardiac and cardiopulmonary indications. These include various cardiac rhythms, ejection fraction severity, heart failure, sleep apnea, myocardial infarction, QT interval prolongation, and hemodynamic measurements like cardiac output and stroke volume.

Related Tools

Cardiomatics
Cardiomatics
Cardiology AI
Cardiomatics is a cloud-based, AI-powered software for analyzing ambulatory (Holter) ECG tests, using clinically validated algorithms to provide accurate and high-quality results for cardiac diagnostics. It aims to streamline ECG analysis, reduce interpretation time, and improve diagnostic accuracy for various heart conditions.
SafeBeat Rx App
SafeBeat Rx, Inc.
Cardiology AI
An AI application designed to support safe pharmacological treatment and monitoring for cardiac arrhythmias.
PreemptiveAI Clinical SDK
Measure Labs, Inc. (Dba Preemptiveai, Inc.)
Cardiology AI
A clinical software development kit using AI to model and predict cardiovascular health metrics, aiming to shift healthcare from reactive to proactive by providing early health risk signals.
Clarius Ejection Fraction AI
Clarius Mobile Health Corp.
Cardiology AI
Clarius Ejection Fraction AI is an AI-powered ultrasound tool for automated left ventricular ejection fraction calculation, integrated into the Clarius Ultrasound App for real-time cardiac assessments.
Automated Aortic Stenosis Software (AutoAS)
Multiple companies are developing Automated Aortic Stenosis Software (AutoAS) or similar AI-powered solutions. Notable ones include iCardio.ai, Us2.ai, AccurKardia, HeartSciences Inc., and Echo IQ.
Cardiology AI
Automated Aortic Stenosis Software (AutoAS) is an ultrasound application by GE Medical Systems that provides automated assessment of aortic stenosis to enhance diagnostic efficiency and consistency.
ECG-AI Pulmonary Hypertension (PH) 12-Lead algorithm
Anumana
Cardiology AI
An AI algorithm that analyzes standard 12-lead ECG recordings to detect signs of pulmonary hypertension, aiming for earlier diagnosis and improved patient outcomes.

See all Cardiology AI tools →

Suggest an Edit → | Last Verified: 2026-04-18 | First Added: 2026-04-18
AI Tool Finder
AI-powered search. Results may not be comprehensive.